drugset / Trial / NCT04869800

Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg

NCT04869800

Phase 1 Completed 32 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398

Timeline

Start
2021-05-27
Primary completion
2021-06-07
Completion
2021-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg
Subject Lobeglitazone Small molecule 0.5 mg